Moderna Completes Enrollment in Its Late-Stage Coronavirus Vaccine Trial

Moderna (NASDAQ: MRNA) announced today that it has completed enrollment in the 30,000-participant study of mRNA-1273, the company's vaccine designed to protect against the novel coronavirus that causes COVID-19. The biotech slowed enrollment toward the end of the study because it was specifically recruiting minorities to increase the diversity of participants in the clinical trial. In the end, the study enrolled 37% minorities, similar to the diversity of the U.S. population.